** Shares of therapy developer Dyne Therapeutics DYN.O fall 19.03% to $11.20
** Co revises timelines for data updates and submission for its genetic disorder therapy DYNE-101 after meeting with FDA
** DYNE-101 is being studied for the treatment of myotonic dystrophy type 1, a genetic disorder causing progressive muscle weakness and wasting
** Co revises main goal in the registration expansion cohort to change from baseline in middle finger myotonia, a symptom which causes delayed muscle relaxation, as measured by video hand opening test at 6 months, compared to placebo
** Data from the trial is now expected in mid-2026, compared to first half of 2026 expected previously
** Also pushes submission seeking accelerated approval to late 2026 from H1 2026
** Stock down ~47% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。